Atrasentan
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB06199 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 19 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | amenorrhea (disease) | KG + DL |
| 2 | Leydig cell hypoplasia due to LH resistance | KG + DL |
| 3 | 46,XY disorder of sex development due to impaired androgen production | KG + DL |
| 4 | kyphoscoliotic heart disease | KG + DL |
| 5 | pulmonary hypertension | KG + DL |
| 6 | HER2 positive breast carcinoma | KG + DL |
| 7 | primary hereditary glaucoma | KG + DL |
| 8 | glaucoma | KG + DL |
| 9 | hypogonadotropic hypogonadism with or without anosmia | KG + DL |
| 10 | progesterone-receptor negative breast cancer | KG + DL |
| 11 | normal breast-like subtype of breast carcinoma | KG + DL |
| 12 | progesterone-receptor positive breast cancer | KG + DL |
| 13 | breast tumor luminal A or B | KG + DL |
| 14 | malignant catarrh | KG + DL |
| 15 | infectious bovine rhinotracheitis | KG + DL |
| 16 | open-angle glaucoma | KG + DL |
| 17 | homozygous familial hypercholesterolemia | KG + DL |
| 18 | obsolete patella aplasia, coxa vara, and tarsal synostosis | KG + DL |
| 19 | coxopodopatellar syndrome | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.